Abstract
The article is devoted to the use of sodium-glucose cotransporter type 2 inhibitors in patients with type 2 diabetes mellitus and chronic heart failure drawing the example of clinical studies with Empagliflozin. Key results of the clinical studies are considered, thanks to which it can be argued that patients with type 2 diabetes mellitus and atherosclerosis-associated diseases, including chronic heart failure, have advantages in predicting cardiovascular outcomes when using hypoglycemic drugs and adding Empagliflozin to standard cardiovascular therapy.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
